The earnings call presented a generally positive outlook for Corvus Pharmaceuticals, with significant net income growth, successful warrant exercises boosting cash position, and promising Phase 1 trial results for soquelitinib. Despite the increase in R&D expenses and a decrease in cash reserves, the company's financial position remains robust, supported by the recent warrant exercise.

Company Guidance -

Q2 2025

During the Corvus Pharmaceuticals First Quarter 2025 Business Update and Financial Results Conference Call, the company provided comprehensive guidance on their financial performance and clinical trial advancements. The research and development expenses for Q1 2025 increased to $7.5 million compared to $4.1 million in Q1 2024, due to higher clinical trial and manufacturing costs. Net income for Q1 2025 was $15.2 million, benefiting from a $25.1 million noncash gain from the change in fair value of Corvus' warrant liability. As of March 31, 2025, Corvus had $44.2 million in cash and equivalents, with additional $31.3 million from exercised warrants expected to fund operations into Q4 2026. The company reported encouraging Phase 1 data for soquelitinib in atopic dermatitis, highlighting favorable safety and efficacy, particularly in Cohort 3, which showed a 71.1% reduction in EASI scores. This data supports the potential for longer treatment duration to improve outcomes, leading to protocol amendments for an extended cohort and plans for a Phase 2 trial initiation by year-end. The guidance reflects ongoing efforts to advance soquelitinib across multiple fronts, including the registrational Phase 3 trial for T-cell lymphoma and a Phase 2 trial for autoimmune lymphoproliferative syndrome (ALPS), with potential initial ALPS data by late 2025 or early 2026.

Significant Increase in Net Income

Corvus Pharmaceuticals reported a net income of $15.2 million for Q1 2025, compared to a net loss of $5.7 million in Q1 2024, largely due to a $25.1 million noncash gain from changes in the fair value of warrant liability.

Successful Warrant Exercise

Holders of 8,945,000 common stock warrants exercised all their warrants, resulting in cash proceeds of approximately $31.3 million, extending operational funding into Q4 2026.

Encouraging Phase 1 Trial Results for Soquelitinib

Phase 1 trials for soquelitinib in atopic dermatitis showed promising safety and efficacy, with Cohort 3 achieving a 71.1% mean reduction in EASI score and 63% of patients achieving EASI 75.

Strong Cash Position

As of March 31, 2025, Corvus had cash, cash equivalents, and marketable securities totaling $44.2 million, with additional warrant proceeds increasing this amount.

Corvus Pharmaceuticals (CRVS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CRVS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	-0.13 / -	-0.07	―	―	―
May 08, 2025	2025 (Q1)	-0.12 / -0.13	-0.12	-8.33% (-0.01)
Mar 25, 2025	2024 (Q4)	-0.12 / -0.18	-0.14	-28.57% (-0.04)	―
Nov 12, 2024	2024 (Q3)	-0.11 / -0.60	-0.12	-400.00% (-0.48)	―
Aug 06, 2024	2024 (Q2)	-0.12 / -0.07	-0.14	50.00% (+0.07)	―
May 06, 2024	2024 (Q1)	-0.14 / -0.12	-0.17	29.41% (+0.05)	―
Mar 19, 2024	2023 (Q4)	-0.12 / -0.14	-0.21	33.33% (+0.07)	―
Nov 07, 2023	2023 (Q3)	-0.12 / -0.12	-0.32	62.50% (+0.20)	―
Aug 08, 2023	2023 (Q2)	-0.14 / -0.14	-0.18	22.22% (+0.04)	―
May 08, 2023	2023 (Q1)	-0.16 / -0.17	-0.18	5.56% (<+0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CRVS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$3.35	$4.43	+32.24%
Mar 25, 2025	$3.93	$3.35	-14.76%
Nov 12, 2024	$8.69	$8.87	+2.07%
Aug 06, 2024	$3.00	$3.29	+9.67%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Corvus Pharmaceuticals Inc (CRVS) report earnings?

Corvus Pharmaceuticals Inc (CRVS) is schdueled to report earning on Aug 12, 2025, TBA (Confirmed).

What is Corvus Pharmaceuticals Inc (CRVS) earnings time?

Corvus Pharmaceuticals Inc (CRVS) earnings time is at Aug 12, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CRVS EPS forecast?

CRVS EPS forecast for the fiscal quarter 2025 (Q2) is -0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing